Citi Pharma (KAR:CPHL) EPS (Diluted): ₨ (TTM As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KAR:CPHL Citi Pharma Ltd KAR:CPHL
15 GF Score
Price ₨74.81
! 1 Warning Sign
View Full Analysis

What is Citi Pharma EPS (Diluted)?

Citi Pharma KAR:CPHL -0.36% 15 EPS (Diluted) is ₨ as of . 20. GuruFocus rates KAR:CPHL with a GF Score™ of 15/100. The stock has 1 warning sign investors should review.

Citi Pharma's Earnings per Share (Diluted) for the six months ended in . 20 was ₨0.00.

Citi Pharma's EPS (Basic) for the six months ended in . 20 was ₨0.00.

Citi Pharma's EPS without NRI for the six months ended in . 20 was ₨0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Citi Pharma  (KAR:CPHL) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Citi Pharma EPS (Diluted) Related Terms

Citi Pharma EPS (Diluted) Historical Data

* Premium members only.

The historical data trend for Citi Pharma's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citi Pharma EPS (Diluted) Chart

Citi Pharma Annual Data
Trend
EPS (Diluted)

Citi Pharma Semi-Annual Data
EPS (Diluted)

KAR:CPHL vs ZTS, UTHR, VTRS: EPS (Diluted) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Citi Pharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Citi Pharma PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citi Pharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where Citi Pharma's PE Ratio falls into.


KAR:CPHL
15GF Score
Citi Pharma Ltd KAR:CPHL
EPS (Diluted) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Citi Pharma EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Citi Pharma's Diluted EPS for the fiscal year that ended in . 20 is calculated as

Diluted EPS (A: . 20 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-)/0
=

Citi Pharma's Diluted EPS for the quarter that ended in . 20 is calculated as

Diluted EPS (Q: . 20 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-)/0
=

Frequently Asked Questions Learn more about EPS (Diluted) →
What does a EPS (Diluted) of ₨ mean?
Citi Pharma (KAR:CPHL) has a EPS (Diluted) of ₨ as of . 20. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Citi Pharma and its competitors.
Is Citi Pharma's EPS (Diluted) too high?
Citi Pharma's current EPS (Diluted) is ₨. Overall, Citi Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Citi Pharma's EPS (Diluted) compare to ZTS and UTHR?
Citi Pharma's EPS (Diluted) of ₨ can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Diluted) for a Drug Manufacturers company?
A good EPS (Diluted) depends on the Drug Manufacturers industry context. However, EPS (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Diluted) mean?
A high EPS (Diluted) can signal that a stock is expensive relative to its fundamentals. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Citi Pharma and its competitors. Citi Pharma's current EPS (Diluted) is ₨. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citi Pharma stock overvalued right now?
Citi Pharma (KAR:CPHL) has a current EPS (Diluted) of ₨. The current EPS (Diluted) is ₨. Citi Pharma's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Diluted) calculated?
EPS (Diluted) is calculated from a company's financial statements. For Citi Pharma (KAR:CPHL), the current EPS (Diluted) is ₨ as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citi Pharma Business Description

Address 588 Q Block, M.A., Johar Town, Lahore, PB, PAK
Citi Pharma Ltd is engaged in the manufacturing and sale of pharmaceuticals, medical chemicals and botanical products. Its product portfolio includes API segment, Formulation segment, Cephalosporin formulation, and Nutraceuticals. The API segment includes Paracetamol, Penicillin/Amoxicillin, Levofloxacin, Cefixime/Cephalosporin, Ciprofloxacin, Cephradine, Norfloxacin, Aspirin, and Ibuprofen.
15GF Score

Get the complete analysis for KAR:CPHL

EPS (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨74.81
Price